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Abstract: Choline kinase (ChoK) is a cytosolic enzyme that catalyzes the phosphorylation of choline
to form phosphorylcholine (PCho) in the presence of ATP and magnesium. ChoK is required for the
synthesis of key membrane phospholipids and is involved in malignant transformation in a large
variety of human tumours. Active compounds against ChoK have been identified and proposed as
antitumor agents. The ChoK inhibitory and antiproliferative activities of symmetrical bispyridinium
and bisquinolinium compounds have been defined using quantitative structure–activity relationships
(QSARs) and structural parameters. The design strategy followed in the development of the most
active molecules is presented. The selective anticancer activity of these structures is also described.
One promising anticancer compound has even entered clinical trials. Recently, ChoKα inhibitors
have also been proposed as a novel therapeutic approach against parasites, rheumatoid arthritis,
inflammatory processes, and pathogenic bacteria. The evidence for ChoKα as a novel drug target for
approaches in precision medicine is discussed.
Keywords: phospholipids metabolism; choline kinase; bispyridinium compounds; bisquinolinium
compounds; QSAR; anticancer drugs; rheumatoid arthritis; parasites; pathogenic bacteria; inflamma-
tory disease
1. Introduction
Alteration of cell metabolism is a frequent event in human diseases [1]. In some
instances are a necessary requirement, such as in the case of cancer onset and progression.
A typical feature of cancer cells is an increased metabolic rate which supports unregulated
growth and higher duplication rates. In keeping with this requirement, aerobic glycolysis,
glutamine catabolism and lipid metabolism are frequently up-regulated in tumours [1]. As
a key event, the pathways involved in the generation of the major phospholipids, such
as cytidine diphosphate-choline (CDP-choline) and cytidine diphosphate-ethanolamine
(CDP-ethanolamine), are frequently altered in human tumours. One of the enzymes that
regulate these pathways is Choline kinase α (ChoKα). Evidence that ChoKα plays a critical
role in many human diseases is increasingly being accumulated, and ChoKα has become
the focus of a targeted therapeutic strategy [2].
As a consequence, small molecule inhibitors and small interfering RNA (siRNA)
that interfere with the function of ChoKα have been designed. These reagents have
proven to be effective and selective anticancer drugs [2]. We describe here how the most
active antiproliferative and antitumoral agents against ChoK were designed by relying on
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quantitative structure–activity relationships (QSARs) and structural parameters. The initial
framework of these inhibitors was based on symmetrical bispyridinium and bisquinolinium
structures.
ChoKα inhibitors have also been proposed as a novel therapeutic approach against
malaria, rheumatoid arthritis, pathogenic bacteria and inflammatory processes [3]. The aim
of this review is to recount the history of the development of ChoKα inhibition therapies
against human diseases and to summarize the most striking findings in this field. It is a
fascinating journey from bench to the bedside. In addition, there are many paths yet to be
fully explored in areas of illnesses other than cancer.
2. The ChoK Family in Humans
In humans, two genes code for the enzymatic activity responsible for the generation
of phosphorylcholine (PCho) designated as CHKA and CHKB. Located in chromosomes
11q13.1 (CHKA) and 22q13.33 (CHKB), they code for proteins of ca. 50 kDa (ChoKα) and
45 kDa (ChoKβ, 395 amino acids) [4–6]. The CHKA gene originates by differential splicing
ChoKα1 (52 kDa, 457 amino acids) and ChoKα2 (50 kDa, 439 amino acids) (Figure 1).
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Figure 1. ChoK characteristics. ChoK catalyzes the phosphorylation of choline, rendering phos-
phorylcholine. This reaction requires Mg2+ and ATP. In humans, two distinct genes, CHKA and
CHKB, code for the ChoK enzymes. The locus of these genes is indicated. CHKA generates ChoKα1
and ChoKα2 by differential splicing. Their molecular weight and size are included as well as their
intracellular location.
There is an overal sequence identity of 56 bet een Cho α and Cho β rotei s.
evert eless, t e see to serve dif erent metabolic and biological functions. ChoKα is
essential for ouse [7] and plant [8] embryo development. A ChoKα knockout cannot be
rescued by ChoKβ [7]. ean hile, ChoKβ is dispensable in ice and a ChoKβ Knockout
(ChoKβKO) leads to a non-lethal, rostr caud l muscular dystrophy and forelimb deformity
due to decreased levels of phosphatidylcholine [9] that can be rescued by ChoKα [10].
More recently, the role of ChoKβ in bone homeostasis in mice has been demonstrated [11].
This result is consistent with the fact that pharmacological inhibition of ChoK activity in
human osteoblasts results in defective mineralization in vitro [12]. In humans, mutations
in the CHKB gene lead to similar pathology [13]. Finally, in Arabidopsis, there are four
Choline-Ethanolamine Kinase (CEK) genes related to choline (Cho) and ethanolamine (Etn)
phosphorylation, with different roles in metabolism and development [14].
Additional enzymatic analyses revealed differential activity patterns for ChoKα and
ChoKβ, φ υ ρ τ η ε ρ σ υ π π o ρ τ ι ν γ different physiological roles. Although both
have Cho kinase and Etn kinase activities under in vitro conditions, in whole cells assays
they divert. ChoKα still has both activities but ChoKβ has only the ethanolamine kinase
activity [15]. Furthermore, ChoKβ does not compensate for decreased phosphatidylcholine
(PC) biosynthesis in ChoKα+/− heterozygous mice. ChoKα production is sufficient to
maintain normal PC levels in most tissues, but not in limb muscles of ChoKβ KO mice.
Furthermore, phosphatidylethanolamine (PE) levels are unaffected in ChoKβ KO mice, a
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result which suggests that PE homeostasis is fully maintained when the ChoKα protein is
intact [9]. Again, in Arabidopsis, substrate specificity for Cho and Etn are distinct for the
four CEK enzymes [14] and resembles the situation described in mammalian cells [15].
The crystal structure of human ChoK demonstrates that this enzyme forms a dimer
(doi:10.2210/pdb2CKQ/pdb; doi:10.2210/pdb5EQY/pdb) [16,17]. This structural feature,
confirmed in enzymatic analysis may have important biochemical and biological conse-
quences since different levels of enzymatic activity for homo- and heterodimers have been
reported, with the ChoKα homodimer as the most active and the ChoKβ homodimer as
the least active [18,19]. Furthermore, a balance of expression of the two isoforms may
have a differential effect on the regulation of the cell cycle [18,19]. Dimerization ratios may
therefore serve as a complex regulatory mechanism for enzyme function, though further
work has to be done to clarify this system.
3. ChoKα in Cancer: A Promissing Therapeutic Target
ChoKα is overexpressed in a large diversity of human tumours including breast [20],
lung [21–23], colorectal [21,24], bladder [25], prostate [21,26–28], ovary [29], endome-
trial [30], pancreas [31], liver [32–35], esophagus [36], and T-cell lymphoma [37]. ChoKα
overexpression has also been reported in osteosarcoma tumour-derived cancer cells [12],
Hepatitis B Virus (HBV)-induced hepatocarcinomas [38,39], breast, colon- and liver-derived
cancer cells [40], glioblastoma- [41] and glioma-derived cell lines [42], pancreatic tumour-
derived cell lines [31,43] and T-cell acute lymphoblastic leukemia (T-ALL) primary cells and
commercial cell lines [44]. In addition, ChoKα expression levels appears to be a marker of
cancer prognosis, aggressiveness or metastasis, in lung [22,23], breast [45,46], bladder [25],
prostate [26,27], ovary [29], colorectal [24], esophageal squamous cell carcinomas [36],
liver [34,35] and B-Cell lymphomas [47,48]. In breast cancer, it has been associated with
ER− status, increased invasiveness, and drug resistance [20,45,46,49,50].
Since ChoKα has an established role in the onset and progression of human can-
cers, this enzyme was proposed as a novel therapeutic target for cancer [2]. Therefore,
a program for the design and synthesis of specific inhibitors (see Section 4 below) was
established. siRNA attenuation of ChoK production was also used to support the proof
of concept [51–53]. Thus, small molecules and specific siRNAs with potent antitumor
activities both in vitro and in experimental animal models have been developed.
To further support the importance of ChoKα as a target for cancer therapy, ChoKα
inhibition has been used in combinatorial regimes and showed a potent antitumor effect
that synergizes with 5-FU in breast and colon cancer cells [54–56] and reverses resistance
to TRAIL in colorectal [57] and ovarian cancer cells [58]. Similar synergic effects have been
obtained with pancreatic ductal adenocarcinoma-derived cancer cells with gemcitabine,
5-FU or oxaliplatin [31], and for lung cancer cells with acid ceramidase inhibitors [59] or
cisplatin (Lacal, unpublished).
PC synthesis is an absolute requirement of cancer cells in order to proliferate. Thus,
inhibition of ChoKα has been shown to have therapeutic effects in a variety of tumor-
derived cancer cell lines and tumor xenografts [2,3]. Blocking this metabolic pathway
has been shown to be non-toxic to normal, primary cells as well as immortalized non-
tumorigenic cells, implying that different responses are activated in tumorigenic and
non-tumorigenic cells in different cell systems [60–63].
A large number of studies use magnetic resonance spectroscopy (MRS), high-resolution
magic angle spinning MRS (HR-MAS MRS) or positron emission tomography (PET) to
determine ChoK levels or their products as biomarkers in cancer diagnosis and progno-
sis have been reviewed recently. Therefore, although this is a very important field in
development, these techniques will not be the subject of this review.
4. Design of ChoKα Inhibitors as a Precision Medicine Strategy
The cost of drug discovery is far too high to be led solely by trial and error. In
computer-aided drug design, quantitative structure–activity relationship (QSAR) studies
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are an effective and useful approach. A QSAR study attempts to understand differences in
the biological activities of a group of congeners in terms of molecular changes induced by
substituent changes.
The most potent ChoK inhibitor known in the early 1990s was hemicholinium-3 (1,
HC-3) with an IC50 for ChoK inhibition ex vivo of 500 µM using recombinant ChoK, and
an IC50 against the human HT-29 cell line of 2.5 mM [64]. A high affinity paralyzing
respiratory effect is induced by HC-3 [65], which is a competitive inhibitor of Cho transport.
As a result, 1 cannot be used as an antiproliferative agent in vivo. Improving the potency
and diminishing the toxicity of 1, by changing its specificity and antiproliferative activity,
was the first step in developing potential anticancer drugs that target ChoK. The ChoK
inhibitory and antiproliferative activities of symmetrical bispyridinium and bisquinolinium
compounds have been defined using quantitative structure–activity relationships (QSARs)
and structural parameters. We will review this strategy in the following sections.
4.1. QSAR Studies between Ex Vivo ChoKα Inhibition and The Electronic Effects of Substituents
at Position 4 of The Pyridinium Moieties
Two choline-like chains comprising quaternary groups are bound to the central
biphenyl system in the HC-3 structure, forming oxazonium rings in solution [65]. The
1,4-oxazonium moieties of 1 were replaced with pyridinium rings with various substituents
at position 4 in order to investigate their electronic effects. The substitution could be carried
out at position 2 of the pyridinium ring, in which the possible electronic effects (inductive
and mesomer) could also be operational; however, in the latter position, the sterical effect
might have masked or altered the electronic effect. Therefore, in our earlier sudies we
eliminated the possibility of substitution at the position adjacent to the N+. We have used
the 1,2-ethylene(bisbenzyl) moiety as a linker to maintain the number of atoms between
the two positively charged nitrogen atoms of 1 (Figure 2).
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The co pounds ere screened in an ex vivo syste using the hu an reco binant
ChoK as a target. e deter ined the effect of our co pounds on the ChoK enzy atic
activity regardless of other confounding factors such as permeability into cells, special cel-
lular conditions, intracellular modifications of compounds or compartmentalization. ChoK
inhibitors were also tested on the HT-29 cell line to see how they affected cell proliferation
in tumor cells [66]. This cell line was developed from a colon adenocarcinoma, one of the
most common solid human cancers that are resistant to chemotherapy, making these cells
suitable for the production of new antitumor drugs. The Ghose–Crippen modified atomic
contribution method (ATOMIC5 option) [67] of the PALLAS 2.0 software [68] was used
to measure the clog P (calculated log P) values of the bis-salts. πspacer is the linker sub-
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stituent constant and πcat head is the –CH2–C6H4–(CH2)n–C6H4–CH2– group substituent
constant, determined with the PALLAS 2.0 program [67] Ghose–Crippen modified atomic
contribution method (ATOMIC5 option) [67].
The activity against the HT-29 cell line is, on average, higher than the activity against
ChoK. Thus, the symmetrical bisquaternized salts may be affecting a different part of the
pathway in this tumor cell line (see Tables 1–3).
Table 1. Compounds 2–12: structures, biological effects and parameter values.
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2, MN58B  –NMe2  17.0  2.00  −0.88  −2.83  0.18 e 
3  –NH2  23.0  4.00  −0.80  −4.67  −1.23 e 
4  –CH2OH  100  >100  −0.07  −4.25  −1.03 e 
5  –CH3  100  20.0  −0.16  −1.82  0.56 e 
6  –COOH  136.7  >1000  0.11  −3.50  −0.32 e 
7  –C≡N  >1000  200  0.08  −3.15  −0.57 e 
8  –N(Allyl)2  17.0  0.55  −0.80 f  −0.44  1.34 e 
9  ‐pyrrolidino  20.0  1.00  −0.85 f  −1.94  0.59 e 




15.0  0.40  −0.86 f  0.09  1.60 e 
12  –NMePh  6.4  0.34  −0.78 f  0.37  1.67 e 
a All values are the mean of two  independent determinations performed  in duplicate. b Recombi‐





All  of  the  R4  substituents  are  either  electron‐releasing,  neutral,  or  elec‐
tron‐withdrawing  (–NMe2,  –NH2,  –CH2OH,  –Me,  –COOH,  –C≡N).  The  electronic  pa‐

















2, N58B –NMe2 17.0 2.00 −0.88 −2.83 0.18 e
3 –NH2 23.0 4.00 −0.80 −4.67 − .23 e
4 –CH2OH 100 >100 −0.07 −4.25 −1.03 e
5 –CH3 100 20.0 −0.16 −1.82 0.56 e
6 –COOH 136.7 >1000 0.11 −3.50 −0.32 e
7 –C≡N >1000 200 0.08 −3.15 −0.57 e
8 –N(Allyl)2 17.0 0.55 −0.80 f −0.44 1.34 e
9 -pyrrolidino 20.0 1.00 −0.85 f −1.94 0.59 e
10 -piperidino 9.60 0.40 −0.89 f −0.93 0.85 e
11 -perhydroazepino 15.0 0.40 −0.86 f 0.09 1.60 e
12 –NMePh 6.4 0.34 −0.78 f 0.37 1.67 e
a All values are the mean of two independent determinations performed in duplicate. b Recombinant human
ChoK was used as a target, σR: Electronic parameter for resonance effects (ref. [69]). c in vitro assay carried out on
the HT-29 cell line, Predict d by using the Ghose-Crippen modified atomic contribution system (ATOMIC5 option,
ref. [67]) of the PALLAS 2.0 program [68]. d πR4 = clog PR4 − clog PH; clog P values have been calculated using
the CDR option of PALLAS 2.0 program. e See ref. [70]. f These values were estimated by 13C NMR spectroscopy
(see ref. [71]).
Table 2. Structures, activity data and parameter used for the generation of QSAR Equation (3).
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Comp.  X  Y  n  (IC5 )ex vivo  (IC50)HT‐29  Clog P b 
Comp. X Y n (IC50)ex vivo(µM) a
(IC50)HT-29
(µM) a Clog P
b
13 =N+– =CH– 0 50 10 −
14 =N+– =CH– 1 100 6.02 −0.86
15 =N+– =CH– 2 34 4 −0.43
16 =N+– =CH– 3 9 2.5 0.08
17 =CH– =N+– 0 >100 ND c −0.85
18 =CH– =N+– 1 60 20 −1.00
19 =CH– =N+– 2 60 20 −0.57
20 =CH– =N+– 3 20 2 −0.06
a All values are the mean of two independent determinations performed in duplicate. b Recombinant human ChoK
was used as a target, Predicted by using the Ghose-Crippen modified atomic contribution system (ATOMIC5
option, ref. [67]) of the PALLAS 2.0 program [68]. c in vitro assay carried out on the HT-29 cell line, ND:
Not determined.
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Table 3. Compounds 21 and 22: structures, biological effects and parameter values.
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(µ ) a σR
b clog P c πR4 d
21 –NH2 10.0 2.00 −0.80 −2.13 −1.23
22 –NHCOBut 10.5 4.74 −0.35
e 1.40 2.18
a All values are the mean of two independent determinations performed in duplicate. b Recombinant human
ChoK from yeast was used as a target, σR: Electronic parameter for resonance effects (ref. [69]). c in vitro assay
carried out on the HT-29 cell line, Predicted by using the Ghose-Crippen modified atomic contribution system
(ATOMIC5 option, ref. [67]) of the PALLAS 2.0 program [68]. d πR4 = clog PR4 − clog PH; clog P values have been
calculated using the CDR option of the PALLAS 2.0 program. e We have used the acetamido value instead of the
pivaloylamino group σR value because the latter value was unavailable (ref. [69]).
All of the R4 substituents are either electron-releasing, neutral, or electron-withdrawing
(–NMe2, –NH2, –CH2OH, –Me, –COOH, –C≡N). The electronic parameters for resonance
effect (σR) were published by Charton [69], and the following correlation Equation (1)
emerges from data of Table 1 [64,72]:
p(IC50)ex vivo = 3.92 (±0.00) − 0.92 (±0.06) σR
n = 5, r = 0.994, s = 0.052, F1,3 = 250.13 (significance at α < 0.001)
(1)
where, pIC50 = −log IC50, bearing in mind that the higher the value of pIC50 the more
potent is the compound, n is the number of compounds, r is the correlation coefficient, s is
the standard deviation, F is the F ratio between the variances of observed and calculated
activities, and data within parentheses are standard errors of estimate.
The inhibitory potency of the compounds is unrelated to their inductive effect [64],
but is well correlated with their resonance effect. This is in line with traditional chemical
principles. The positively charged ring nitrogen is in direct conjugation with R4. The higher
the resonance effect of R4, the better the delocalization of the positive charge. Following
these findings, researchers looked for a substituent with a higher electron-releasing effect
than the –NH2 or –NMe2 groups. As a result, endocyclic amino groups like pyrrolidino,
piperidino, and perhydroazepino may have a stronger electron-releasing effect. The N-
methylanilino and the N-diallyl groups were also tested. Furthermore, when compared to
the –NH2 and –NMe2 groups, their higher lipophilicities can aid in the antiproliferative
activities of even more active compounds [70].
13C NMR spectroscopy was used to estimate the unknown σR descriptors for the
diallylamino, pyrrolidino, piperidino, perhydroazepino, and N-methylanilino moieties [71].
The totality of the ten compounds synthesized until then give rise to Equation (2):
p(IC50)ex vivo = 3.92 (±0.11) − 1.09 (±0.15) σR
n = 10, r = 0.928, s = 0.181, F1,8 = 49.78 (significance at α < 0.001)
(2)
MN58b is a member of the first generation of HC-3 derivatives that were used as a
prototype for studying ChoKα effects in both normal and tumor cells [2].
4.2. Ex Vivo ChoK Inhibition and Clog P: QSAR Studies
We chose structures with the following characteristics to investigate the potential
effect of lipophilicity on ChoK inhibition in ex vivo conditions [72]:
(a) Cationic heads with a “zero electronic effect”, i.e., hydrogen at position 4, that allow the
positive charge to be dispersed to a large extent. We used unsubstituted quinolinium
and isoquinolinium rings to achieve this.
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(b) Aralkyl spacers with different number of methylene groups.
ChoK inhibition activity is found to correlate with lipophilicity for these compounds,
as shown in Equation (3):
p(IC50)ex vivo = 4.83 (±0.09) + 0.81 (±0.15) clog P
n = 7, r = 0.922, s = 0.151, F1,5 = 28.57 (significance at α < 0.005)
(3)
On the basis of Equation (3), we propose that hydrophobic interactions between the
bisalts 13–20 and ChoK can occur. The QSAR greatest contribution is that it has provided
a comprehensive and reasonably complete quantitative understanding of the role of hy-
drophobicity in drug action [73]. Hydrophobicity is related not only to absorption and
distribution but also to the interactions with ChoK active site. Apart from electrostatic in-
teractions, it appears that the cationic heads and spacers between the two positive nitrogen
atoms, hydrophobilically bind to the enzyme more strongly. Non-covalent interactions in
aqueous solution are dominated by hydrophobic interactions. At hydrophobic surfaces,
loosely connected water molecules have a degree order and are therefore in an undesirable
entropic degree. The interaction of a drug hydrophobic areas with its binding site releases
the organized water molecules, resulting in an increase in entropy. The planar quinolinium
and isoquinolinium cations have been shown to bind to artificial receptors, with aromatic
rings, more strongly than the alkylammonium cations [74].
4.3. Combining The Electronic and The Lipophilic Effects in The Same Molecules
The electron-releasing potential of the substituent at position 4 of the heteroaromatic
cationic head (Table 1) and the lipophilicity of the bissalts (Table 2) had a significant effect in
ChoK inhibition. Therefore, in order to improve the inhibitory efficacy, we combined these
two properties in the same molecule and prepared compounds 21 and 22 (Table 3). The
-NH2 group is an electron-releasing group that should be strong, while the pivaloylamino
moiety should be weak. We used the corresponding value of the very similar acetamido
group instead (σR = −0.35) [69] because the latter σR value was unavailable. The results
met our standards, so we tried to link the ChoK inhibitory potency with the two descriptors,
resulting Equation (4), in which all the compounds of Tables 1–3 were included:
p(IC50)ex vivo = 4.44 − 0.73 (±0.14) σR + 0.12 (±0.04) clog P
n = 19, r = 0.836, s = 0.241, F2,16 = 18.61 (significance at α < 0.001)
(4)
Our QSAR studies revealed that the efficacy of inhibitors is determined by π at a
particular location on the molecules rather than the overall log P. Equation (5) suits very
well with the use of these site-specific π parameters:
p(IC50)ex vivo = 0.55 − 1.04 (±0.13) σR + 0.63 (±0.15) πspacer + 0.30 (±0.08) πcat head
n = 19, r = 0.917, s = 0.181, F3,15 = 26.46 (significance at α < 0.001)
(5)
In order to obtain Equation (5), we had to accept that for compounds 2–12, the πcat head
was equal to zero (π2H due to the H-2 and H-3 protons of the pyridinium moiety), while
for bisquinolinium and bisisoquinolinium structures 13–22, πcat head is 1.27. πspacer is the
–CH2–C6H4–(CH2)n–C6H4–CH2– group substituent constant, which ranges between 5.14 (n
= 0 of the spacer) and 6.28 (n = 3 of the spacer). The fact that πspacer has a higher coefficient
and values than πcat head leads to the inference that the former is much more significant
than the latter in terms of hydrophobicity. Finally, the positive π-term coefficients indicate
that hydrophobic moieties and electron-donating groups support ChoK inhibitory action,
at least within the context of spacers and heteroaromatic rings used.
4.4. Influence on The Antiproliferative Activity Against The HT-29 Cancerous Cell Line
The final research focused on two aspects: (a) the impact that a variation of the linker
that links the quinolinium cations with electron-releasing groups at position 4 with other
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different groups at positions 3, 7, and 8 of the heterocycle (compounds 23–63) would have
on the ex vivo human inhibitory activity; and (b) the impact of the factors that regulate the
antiproliferative properties of such compounds [66].
Tables 4–6 show the biological results of compounds 23–63, which correspond to series
A, B, and C, as a function of the group at position 7 of the quinolinium ring.
Table 4. IC50 ChoK and HT-29 values for the bisquinolinium derivatives belonging to series A.




the  –CH2–C6H4–(CH2)n–C6H4–CH2–  group  substituent  constant, which  ranges  between 
5.14 (n = 0 of the spacer) and 6.28 (n = 3 of the spacer). The fact that πspacer has a higher 







different groups at  siti s  3, 7, and  8 of  the heterocycle  (compounds 23–63) would 
have on the ex vivo human  nhibitory activity; and (b) the impact of the f ctors that r g‐
ul te the antiprolife ative pr perties  f such compounds [66]. 
Tables 4–6  s   t e biological  results  f  compounds 23–63, which  correspond  to 
series A, B, and C, as a fu ction of the group at position 7 of the quinoli ium ring. 
Table 4. IC50 ChoK and HT‐29 values for the bisquinoliniu  derivatives belonging to series A. 







H  Amino  1.20  1.90 
24  Me  Amino  11.9  4.40 
25  H  Dimethylamino  4.40  1.60 
26  H  Perhydroazepino  0.50  0.50 
27  H  Anilino  1.30  1.60 
28  H  N‐Methylanilino  0.40  0.80 
29  H  4‐Chloro‐N‐methylanilino  2.10  1.50 
30 
Biphenyl‐4,4′‐diyl 
H  Amino  81.1  2.20 
31  Me  Amino  >200  3.30 
32  H  Dimethylamino  39.7  1.70 
33  H  Perhydroazepino  2.20  0.50 
34  H  Anilino  17.8  0.70 
35  H  N‐Methylanilino  3.00  0.60 
36  H  4‐Chloro‐N‐methylanilino  2.00  1.20 
37 
Bibenzyl‐4,4′‐diyl 
H  Amino  80.0  2.00 
38  H  Dimethylamino  10.2  0.50 
39  H  Perhydroazepino  0.60  0.30 
40  H  Anilino  2.30  0.30 
41  H  N‐Methylanilino  1.40  0.70 











H mino 1.20 1.90
24 e Amino 11.9 4.40
25 H Dimethylamino 4.40 1.60
26 H Perhydroazepino 0.50 0.50
27 H Anilino 1.30 1.60
28 H N-Methyla ilino 0.40 0.80
29 H 4-Chloro-N-methylanilino 2.10 1.50
30
Biphenyl-4,4′-diyl
H Amino 81.1 2.20
31 Me Amino >200 3.30
32 H Dimethylamino 39.7 1.70
33 H Perhydroazepino 2.20 0.50
34 H Anilino 17.8 0.70
35 H N-Methylanilino 3.00 0.60
36 H 4-Chloro-N-methylanilino 2.00 1.20
37
Bibenzyl-4,4′-diyl
H Amino 80.0 2.00
38 H Dimethylamino 10.2 0.50
39 H Pe hydroazepino 0.60 0.30
40 H Anilino 2.30 0.30
41 H N-Methylanilino 1.40 0.70
42 H 4-Chloro-N-methylanilino 4.80 0.70
a All values are the mean of two independent determinations performed in duplicate. b Recombinant human
ChoK was used as a target. c in vitro assay carried out on the HT-29 cell line.
Lipophilicity, molar volume, and steric bulk are all factors that influence molar re-
fractivity (MR) [75]. To get rational values for the regression coefficients of the resulting
QSAR equations, the MR values are usually scaled by a factor of 0.1. With the support
of 3D structures, the importance of MR in QSAR equations of certain ligand–enzyme
interactions were interpreted. These studies revealed that π-modeled substituents bind
in a hydrophobic space. Interactions between these substituents with a polar surface will
give rise to a positive sign of MR in a QSAR equation [76,77], while a negative sign or a
nonlinear relationship indicates a limited area or steric hindrance at this binding site [75].
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Table 5. IC50 ChoK and HT-29 values for the bisquinolinium derivatives belonging to series B.













44  Dimethylamino  9.60  0.70 
45  Pyrrolidino  1.20  0.40 
46    N‐Methylanilino  3.10  1.00 




49  Dimethylamino  20.6  0.80 
50  Pyrrolidino  19.8  2.40 
51  N‐Methylanilino  11.4  0.50 




54  Dimethylamino  9.00  0.27 
55  Pyrrolidino  1.00  0.20 
56  N‐Methylanilino  3.50  0.50 


































44 Dimethylamino 9.60 0.70
45 Pyrrolidino 1.20 0.40
46 N-Methylanilino 3.10 1.00




49 Dimethylamino 20.6 0.80
50 Pyrrolidino 19.8 2.40
51 N-Methylanil no 11.4 0.50




54 Dimethylamino 9.00 0.27
55 Pyrrolidino 1.00 0.20
56 N-Methylanil no 3.50 0.50
57 4-Chloro-N-methylanilino 5.70 0.80
a All values are the mean of two indepe nt determinations performed in duplicate. b Recombinant human
ChoK was used as a target. c in vitro ass y carried out on the HT-29 cell line.
Table 6. IC50 ChoK and HT-29 al es for the bisquinolinium derivatives belongi g to series C.
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63 4-Chloro-N-methylanilino 57.5 19.5
a All values are the mean of two independent determinations performed in duplicate. b Recombinant human
ChoK was used as a target. c in vitro assay carried out on the HT-29 cell line.
Equation (6) was obtained after taking into account the volume effects (MR8) (the
subscript refers to the location of the substituen ), the measured global lipophilicity (clog
P), the linker substituent constant, and the electronic parameters (σR) of the R4 substituent
for antiproliferative activity:
p(IC50)HT-29 = − 2.66 − 0.03 (± 0.00) MR82 + 0.10 (± 0.02) clog P + 1.05 (± 0.31)πlinker
− 3.73 (± 0.71) σR
n = 40 (series A, B and C), r = 0.920, s = 0.223, F4,35 = 47.856, α < 0.001
(6)
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The following points should be illustrated from Equation (6): (a) Since the coefficient
of MR8 is a squared negative expression, the existence of a methyl group at position 8 is
detrimental to antiproliferative activity; thus, a hydrogen atom at this position is preferable
because it has a lower MR value; (b) Lipophilicity contributes to the antiproliferative
activity in two ways: on the one hand, it has a global contribution (clog P), and on the
other, it has a particular contribution at a specific location on the molecules (πlinker). Since
both descriptors are orthogonal, their inclusion in the QSAR equation is justified. Since
πlinker has a higher relative contribution in Equation (6) than clog P, it is possible that
favorable hydrophobic interactions between the enzyme and the linker modulate the
inhibitor-ChoK coupling. While raising the global lipophilicity and the linker lipophilicity
would increase antiproliferative activity, solubility was the reason for limiting the spacers
to 3,3′-, 4,4′-biphenyl, and 4,4′-bibenzyl moieties.
Equation (7) is obtained when the experimental p(IC50)HT-29 values are compared with
the theoretical ones determined by Equation (7):
p(IC50)HT-29 exptl = − 0.35 + 1.05 (±0.08) p(IC50)HT-29 theoret
n = 40, r = 0.916, s = 0.220, F1,38 = 198.854 (significance at α < 0.001)
(7)
Since it obtained the best experimental results, compound RSM-932A was selected
for further study. It acts similarly to MN58b in vitro by inducing cell cycle arrest in
nontumorigenic cells and apoptosis in tumor cells [60–63]. RSM-932A has no detectable
toxicity in mice at highly effective doses that lead 77 percent tumor growth inhibition in
in vivo conditions [78]. Indeed, RSM-932A (also known as TCD-717) was the first ChoKα
inhibitor to be studied in humans, in a phase I clinical trial [79].
4.5. Other Symmetrical and Unsymmetrical ChoKα Inhibitors
Other modifications have been carried out to give rise to newly designed structures
64–68 (Figure 3).
Symmetrical bis-charged structures containing minor modifications in the spacer have
been described [80]. Unfortunately, because of their structural homology to choline, double
positively charged chemotypes are correlated with substantial toxicity due to off-target
activities [81]. The lead series described by Zech et al. [81], on the other hand, relies heavily
on basic amines found in methyldiazepanes to bind to the choline site. A primary hydrogen
bond is added by the protonated 1’ nitrogen. It is important to remember that depending
on local conditions like pH, the methyldiazepane moiety may be transiently protonated
or present as a free base. Furthermore, diazepane is used in a wide variety of licensed
medications, mainly to boost solubility or ADME parameters. In most cases, this moiety
does not pose a significant toxicity risk. Compound 68 induced apoptosis at low µM
concentrations in the ChoKα expressing line MDA-MB-415.
From their synthesis to the molecular basis of their binding mode, a review in the
field of ChoK inhibitors was published [82]. The first library of asymmetric bispyri-
dinium derivatives was reported by Rubio-Ruiz et al. [82]. To investigate potential
new binding modes to the enzyme. 4(4-Chloro-N-methylanilino)pyridinium, 1-benzyl-4-
(dimethylamino)pyridinium, and 4-pyrrolidinopyridinium fragments were combined in
these structures, with both positively charged moieties linked with variable linkers. The
plasticity of the choline binding site, the discovery of new exploitable binding sites, and
the allosteric properties of this enzyme are all emphasized as strategies for developing
inhibitors and their selectivity on ChoKα over ChoKβ. Rubbini et al. published a new class
of asymmetrical pyridinium/quinolinium derivatives developed and designed based on
drug optimization. Compound 69 does not promote apoptosis and does not increase the
cleavage of PARP, indicative of caspase activation. It induces a cell-cycle arrest in G1 Phase
and induces senescence in MDA-MB-231 [83].
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Figure 3. Several sym etrical bis-charged (64, 65 [80]), sy arged ( 6 [81]), unsy metrical m no-charged
ChoKα inhibitors (67, 68 [ 2]) and bis-charged ChoKα inhibit rs ( [ ]).
5. ChoKIs Mechanism of Action
The implication of ChoKα in a diversity of human cancers is well established. Its
lack of expression is lethal, implying that its function is essential [7], and its inhibition
leads to either cell arrest in non-tumorigenic cells, or cell death in tumor cells [2,3,60–63].
Since ChoKs use choline and ATP as substrates of the enzymatic reaction, inhibition of
ChoKα activity by direct blockage of the Cho or ATP-binding pockets could be a specific
and effective strategy to block cancer cell proliferation. A number of ChoKIs have been
designed to achieve this goal [82].
However, this strategy has been questioned since V-11-0711, a potent inhibitor of
ChoKα that affect ly its catalytic activity, is not able to induce cell death in breast tumour
cells. Therefor , a non-catalytic function of ChoKα has bee suggested [84,85]. In keeping
with this, a bala ce between ChoKα and ChoKβ may be required for the appropriate
regulation of cell proliferation and reduction of the protein levels of ChoKα may be
required in some cell systems for induction of cell death [19]. Furthermore, a chaperone
activity has been reported for ChoKα [86,87]. If this is correct, effective ChoKαI must be
able to simultan ou ly reduce ChoKα enzymatic activity and intracellular protein lev ls.
The enzymati activity of ChoKα follow a ping-pong mecha ism with an intermedi-
ary phosphorylated conformation that can be used for its inhibition without affecting ATP
and Cho binding by a steric interaction [88,89]. In keeping with this, RSM932A/TCD717
has a unique mechanism of action, different from any other ChoKαI so far described. Its ef-
fect is not competitive with choline or ATP [88] since it does not bind directly in the choline
or ATP pockets as do previously characterized ChoKαIs, but rather in a proximal but novel
location near the surface of the enzyme [90]. This characteristic renders a rather unique
mechanism of action that potentiates its specificity and potent antitumor activity [78].
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Inhibitors such as RSM-932A or specific siRNAs with a drastic reduction of both the
levels of ChoKα and its product, phosphorylcholine, show a drastic and selective induction
of cell death in a large variety of tumor cells. Additionally, it has been suggested that
RSM932A induces a conformational change that expose the unfolded structure of the
enzyme to endogenous proteases resulting is a drastic reduction of the ChoKα protein
levels [62,88]. Consistent with this interpretation, inhibition of ChoKα activity with no
significant reduction of its protein levels may not be sufficient to trigger cell death in tumor
cells [84,85]. However, in glioblastoma cells, inhibition of ChoKα by V-11-0711 is sufficient
to significantly reduce cell viability, invasiveness and clonogenicity. Furthermore, this
antitumoral effect was related to inhibition of the expression of EMT associated genes
mediated by ChoKα, and was synergistic with temozolomide [91]. Thus, the effect on cell
viability by ChoKIs may be cell type dependent.
Several studies have looked into the implications of interfering with ChoK function,
which may clarify how ChoK specific inhibitors (ChoKIs) and ChoK silencing with specific
siRNA operate. ChoK inhibition through pharmacological or siRNA approaches cause
a variety of effects such as loss of mitochondrial potential and cytochrome c release [58],
increased ceramide output [61], ER stress [62], unfold protein response (UPR) [62], and
ROS homeostasis via glutathione levels [92]. Similar effects on ER stress have been reported
in Arabidopsis [93].
Decreased mitochondria function by pharmacological inhibition of ChoKα has been
associated with a reduction of citrate synthase expression and AMPK activation. These
effects are also related to an increase in glucose and acetate uptake in an attempt to
overcome the metabolic stress. The final outcome is the induction of cell death including
apoptosis or necrosis with an exquisite specificity towards cancer cells [60–63,91].
The implication of ChoKβ in cancer is still not resolved. Genetic evidence has clearly
demonstrated a role of ChoKβ in muscular dystrophy [9–13]. Furthermore, ChoKβ in-
hibition by siRNA has no detrimental effect in cell viability, maybe because ChoKα can
supplement its absence as a redundant metabolic enzyme [9]. However, we cannot ex-
clude the possibility of a role of ChoKβ in the modulation of the activity of ChoKα in
different tissues and therefore can still play a critical role in the onset and progression of
tumours [18,19].
6. ChoKα in Drug Resistance
Drug resistance, one of the major burdens in anticancer research, has been also investi-
gated in the ChoK pathway. In NSCLC-derived cells, resistance to ChoKαIs is overcome
by overexpression of acid ceramidase (ASAH1) in keeping with the known mechanism
of action of ChoKαIs of inducing increased levels of ceramides [59,61] and allows the
identification of tumours resistant to treatment with ChoKαIs. Acquisition of resistance
to ChoKαIs has also being found in pancreatic [31] and breast cancer cells (Lacal et al.,
unpublished). In B-Cell lymphomas, resistance to lysine deacetylase inhibitors (KDACI)
is linked to increased ChoKα activity and can be overcome by treatment with ChoKαIs
(48). Similar effects have been reported in TRAIL-resistant colorectal [57] and ovarian
tumours [58] where ChoKαIs can restore sensitivity to TRAIL.
Differences in the response of normal, non-tumorigenic and cancer cells have been
unveiled. Thus, in breast, lung and colon-derived tumor cells, a drastic alteration of the
levels of expression of proteins involved in the regulation of endoplasmic reticulum (ER)
stress and the unfold protein response (UPR) takes place as a consequence of ChoKα
inhibition [62]. A completely different scenario is observed in non-tumorigenic cells,
where a transient and attenuated ER stress response is observed. These alterations in
protein expression occur in parallel with a drastic reduction in cyclin D1, RB and E2F1α
in cancer cells which is not observed in non-tumorigenic cells [62]. Thus, maintenance
of the RB-E2F1α complex in non-tumorigenic cells after ChoKα inhibition induces arrest
in G0/G1 but not cell death [62]. These results are consistent with many studies where a
differential effect was observed in cancer versus non-tumorigenic cells [2,3]. Additionally,
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in Arabinopsis, a similar role for the CEK1 enzyme has been proposed for the management
of ER stress [92].
Likewise, specific interference with ChoKα siRNA drives cancer cells to apoptotic
death [2,3,51–53,55]. By contrast the specific ChoKα inhibitor V-11-0711 (IC50 = 20 nM),
causes reversible growth arrest [84], similar to what is observed in non-tumorigenic cells
with other inhibitors [60,61,93]. These observations suggest that ChoKα plays a role in
cancer cell survival that is outside the PC synthesis pathway [84] in keeping with abundant
information that links ChoKαwith both metabolic and signal transduction functions. These
results are further supported by transcriptome analysis in cancer cells since inhibition of
ChoKα induce alteration of expression levels of genes involved in cell cycle regulation,
apoptosis, and nucleotide metabolism [94–97].
7. ChoKs, More Than Metabolism Enzymes?
In addition to all the reported effects on cell metabolism, interference with ChoKα ac-
tivity and levels has also an effect in signal transduction pathways. ChoKα has been shown
to be phosphorylated by c-Src in breast cancer cells and as a consequence, it associates with
the EGFR and is translocated to the plasma membrane [98]. Phosphorylation takes place
at Y197 and Y333 and increases its activity by 1.40- to 1.68-fold when ChoKα is expressed
along with c-Src or EGFR, respectively, and about 2.5-fold when co-overexpressed with
both EGFR and c-Src [98]. Phosphorylation of ChoKα seems to correlate with a higher cell
proliferation rate. Recently, this interaction has been mapped at the SH3 domain of c-Src
and the poly-proline region N-terminal of ChoKα [99]. The relationship of ChoKα and
EGFR, has also been reported in lung [100] and liver tumors [35] and has been associated
with resistance to EGFR inhibitors [35]. In prostate cancer, ChoKα acts as a chaperone
for the androgen receptor (AR), elucidates a feed-forward signalling loop that maintains
ChoKα expression and as a consequence reinforces AR signaling activity. This chaperone
function confers a growth advantage to cancer cells where ChoKα is overexpressed [89,90].
By contrast, ChoKβ activity is regulated by PKA at residues Ser 39 and Ser 40, a
process that depends on cAMP levels [101]. Phosphorylation of ChoKβ increases its
catalytic efficacy for choline and ATP but not to ethanolamine, and results in an increased
sensitivity to HC-3 inhibition. This could be consistent with that phosphorylation of
ChoKβ may be a mechanism to regulate PC and PE synthesis and that phosphorylation
could modulate the balance of both isoenzymes as previously described [19]. Additionally,
a differential phosphorylation by c-Src and PKA suggests that both isoforms could be
implicated in carcinogenesis although by alternative mechanisms and in different organs.
Regulation of ChoKs is therefore similar to other eukaryotic protein kinases (ePKs)
and follows phosphorylation patterns, in keeping with their proposed common ancestor
and with an early eukaryotic origin. In fact, both ePKs and ChoKs have been suggested to
have played an important role in early evolution of highly complex eukaryotic cells [102].
ERK and AKT phosphorylation are reduced by either pharmacological inhibition or
siRNA silencing of ChoKα in breast and T-cell lymphoma cancer cells [103–105]. Finally,
ChoKα is regulated by PI3K and Ral-GDS, two direct effectors of the Ras oncoprotein [106].
MYC and HIF1 have been involved in the regulation of ChoKα expression [37,107,108],
suggesting that overexpression of ChoKα results from the acidification typical of solid
tumors. HIF1 is modulated in gliomas by 2-HG (2-hydroxyglutarate), the product of IDH1
(isocitrate dehydrogenase 1), resulting in a reduction in ChoK and EtnK activity [109].
ChoKα has been involved in neuronal differentiation [110], a process mediated by
CCAAT/Enhancer binding Protein-β (C/EBPβ) through the CHKA promoter and the
involvement of the ERK1/2 pathway and KDM2B (Lysine Demethylase 2B) as a repres-
sor [111,112]. In keeping with this observation, a relationship with Parkinson’s disease (PD)
has been recently suggested for ChoKα by modulation of Daf-16 location and control of the
lipid content [113]. Finally, ChoKα interacts with the nonstructural protein 5A (NS5A) and
phosphatidylinositol-4-kinase III (PI4KIII), modulating hepatitis C virus (HCV) replication
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through a mechanism that involves the endoplasmic reticulum [114,115]. Inhibition of
ChoKα has therefore a potential antiviral function.
ChoK dysfunction has recently been linked to a variety of other human diseases.
ChoKα deficiency is lethal during early embryo development in mice and Arabidop-
sis [7,8], while ChoKβ is dispensable for embryo viability but required for proper forelimb
development [9–13]. Differential expression patterns [116,117], mitochondrial activity [118],
and neuromuscular junctions [119] are all effects of ChoKβ deficiency in mice. Inactivating
mutations in the CHKB gene have been linked to human muscular dystrophy and myopa-
thy in several recent studies [11,120–128]. Since a lack of ChoKβ activity causes muscular
dystrophy, any intervention that restores ChoKβ activity can help to restore normal muscle
development in this pathological situation.
Regulation of both CHKA and CHKB genes have been reported to follow distinct
patterns. Thus, the ChoKβ is regulated along with the carnitine palmitoyltransferase 1B
(CPT1B) gene and it is involved in the modulation of brown adipose tissue to generate
heat [129]. Curiously, ChoKα is regulated in a robust circadian expression pattern in the
liver and adrenal glands [130]. These findings reinforce the idea of differential physiological
roles for both isoenzymes.
Searching for mechanisms that will allow to control ChoK functions, it is of interest to
remark that two recent reports involve miRNA species in a network of regulatory processes
to control ChoKα levels and function. It has been shown that miR-367-3p targets the 3’-UTR
of the chka mRNA transcript with strong affinity in MCF7 breast cancer cells and, as a
consequence, represses its expression [131]. In the lung cancer cell lines H1355 and A549,
miR-1-3p regulates the EGFR/MAPK/ChoKα signaling pathway through modulation of
the expression of FAM83A (Family with sequence similarity 83, member A) [100] a gene
involved in the onset of lung adenocarcinoma [132]. These interesting findings open the
possibility to explore alternative strategies for the control of ChoKα levels and activity as
therapeutic approaches.
8. ChoKs and ChoKIs of Protozoal Parasites
Roughly 15% of the world population is affected at some point in their lives by an
illness caused by a protozoan parasite. In the developing world, this figure increases to
65%. The available therapies for many of these types of protozoal infections are limited,
inadequate, and increasingly useless as resistant strains emerge. At the same time, market
logic ensures that research and development into novel drug therapies for treating many
of these parasites is limited. Therefore, research into novel drug targets such as choline
kinase is of paramount importance [133].
8.1. Plasmodium falciparum and ChoK
Plasmodium falciparum is a parasite which is the causative agent of malaria, which
is transmitted by mosquitoes. Developing alternatives for the treatment of malaria is
extremely critical: new drug-resistant strains of P. falciparum continuously appear. This
includes strains resistant to artemisinin, the current frontline drug of choice in endemic
regions [134]. Novel drug targets must be established and thoroughly researched, and
drug discovery programs need to focus on discovering inhibitors for these novel target.
One relatively novel drug target is choline kinase, an enzyme in the pathway leading to
the production of Phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
PC and PE are two essential and highly represented phospholipids in found in the
membranes of P. falciparum (40% and 35% of total phospholipids, respectively) [135]. The
essential nature of these phospholipids means that the pathways responsible for their
synthesis can be disrupted to eliminate this parasite [136]. In P. falciparum, as in other eu-
karyotes, PC and PE are synthesized from choline (Cho) or ethanolamine (Etn), respectively,
via the Kennedy pathway. The first enzyme in this pathway in P. falciparum is choline kinase
(pfChoK), which functions both as a choline kinase and an ethanolamine kinase. Impor-
tantly, pf-ChoK is more highly expressed in growth phases of P. falciparum [137]. Inhibition
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of pf-ChoK affects the parasite’s viability in in vitro and mouse models of malaria [88,138].
Therefore, pfChoK is a natural target for inhibition.
The first pfChoKI, hexadecyltrimethylammonium bromid (HBA), was reported in
2007. HBA significantly reduces PCho synthesis (by 57% at 10 µM) and parasite growth
(81% at 20 µM) and reduces parasitemia by 50% in mice with doses of 5 mg/kg [138].
Some promising inhibitors have been discovered by the repurposing of hChoK in-
hibitors [88,139]. This repurposing strategy is effective because the primary structure of
the active site of pf-ChoK (Figure 4), as well as the tertiary structure (Figure 5), are highly
conserved with respect to hChoK [140]. For example, hChoK inhibitors MN58b and RSM-
932A inhibit pfChoK in the micromolar range [88]. These inhibitors also prevent growth of
P. falciparum at the low nanomolar range. In addition, they are effective against both drug-
sensitive and drug-resistant strains. MN58b and RSM-932 also prevent intraerythrocytic
development, which affects parasite egress and invasion. RSM-932A has an uncompetitive
mechanism with respect to choline and ATP while MN58b has a competitive mechanism
with respect to both substrates.
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Figure 4. Alignment of the primary sequences of hChoK, pf-Chok, and sChok using the alignment tool ClustalW. Stars
indicate conserved residues and the positions of the choline kinase bi ing residues of hChoK are marked with a blue circle.
The ATP binding site residues are marked with a red circle. While there is poor overall alignment of sequences, there is
strong conservation in the areas of the ATP and choline binding site, as can be seen by the number of residues that are either
conserved or semiconserved.
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Figure 5. Alignment of the crystal structures of hChok (blue, RCSB accession #2CKO, dimer); pfChok
(cyan RCSB accession #6YXS [140], monomer); and sChoK (purple. RCSB accession 4R77, monomer).
The basic N-terminal and C-terminal domains are shown to be generally conserved. Alignment and
figure generation carried out with the PyMol Package.
Repurposed hChoK inhibitors which selectively inhibited the ethanolamine kinase
function of pf-ChoK were also discovered. These blocked the growth of parasites at IC50s
in the low nanomolar range. These inhibitors also caused a concomitant drop in cellular
PE, leading to cell death [139].
Bisquinolinium bromide salt derivatives were discovered via high-throughput com-
pound screening. These inhibitors were found to have affect P. falciparum growth at
IC50s < 1µM and had IC50s against pf-ChoK in the low µM [141].
8.2. Leishmania infantum and Choline Kinase
Leishmania infantum is the causative agent of Leishmaniasis, a disease found in the
tropics and subtropics and transmitted by phlebotomine sand fly. Leishmaniasis affects
nearly 1 million people a year [142]. There has been an initial study whether or not
ChoK inhibition is an effective strategy for eliminating L, infantum parasites. A number
of quaternary ammonium salts were scr ened, howev r the m st eff ctive inhib tor, (N-
iodomethyl-N,N-dimethyl-N-(6,6-d phenylh x-5-en-1-yl) mmonium iodide, only inhibited
liChoK in the mM ange. Therefore, more work n eds to be carried out to d scov r more
powerful inhibitors gainst liChoK and to assess bility to kill th parasi [143].
8.3. Trypanosoma brucei and Choline Kinase
Trypanos ma brucei is the causativ agent of Human African Try nosomiasis also
known as Africn sl eping sickness. Thi parasite is transmitted by the Tsetse fly. Several
hundred thousand sub-Saharan Africans are infected yearly with this parasite, leading
to 10,000 deaths. This parasite produces a single choline kinase isoform (tbChoK) [144].
Conditional knockouts tbChoK has demonstrated that this enzyme is critical for cell
growth [145]. The only available treatments are often toxic and drug resistant strains have
emerged [146]. To date, we have identified a single drug discovery study which utilized
fragment based screening against tbChoK to identify leads that were effective against
T. brucei at IC50s in the low µM [145]. These results suggest that tbChoK is a promising
drug target.
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9. Bacterial Pathogens and Their ChoKs and ChoKIs
The emergence of bacterial pathogens that are resistant to current antibiotic therapies
underlines the need for continuous research into alternative therapies and the discovery of
novel drug targets. A promising strategy is to exploit information regarding drug targets
in eukaryotic systems and explore their analogs in bacterial systems. This is an ideal,
cost-effective, and efficient strategy, because the same therapies that were developed at
considerable expense in eukaryotic systems can be repurposed as antibiotics and antimi-
crobials. Promising examples of this strategy are bacterial pathways of which ChoK is a
part. These pathways are best characterized in the Gram-positive Streptococcus pneumoniae
and Gram-negative Haemophilius influenzae.
9.1. Streptococcus pneumoniae and Choline Kinase
Choline is an essential nutrient for S. pneumoniae [147] and the choline kinase of S.
pneumoniae (sChoK) is an essential enzyme [148]. This pathogen meets its needs for this
metabolite in part by scavenging choline molecules from host cells using the Pce phos-
phodiesterase [149]. As in eukaryotes, the ChoK of S. pneumoniae (sChoK) phosphorylates
choline (Cho) into phosphorylcholine (PCho). However, the subsequent metabolic path-
ways diverge from the Kennedy pathway: PCho is utilized in the pathways responsible for
the synthesis of bacterial teichoic acids (Figure 6).
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growth. Therefore,  it  follows  that disruption of  any  element of  this pathway,  such  as 
sChoK, is a promising therapeutic avenue to follow. In addition, the same tools used the 
to  inhibit eukaryotic ChoKs are  likely  to be effective against sChoK, particularly  those 
know  to  interact with  the substrate binding sites. This  is because  the choline and ATP 
6. The sChok pathway and how it fi s nto the overall process of teichoic acid assembly. PCho
molecules (purple) are transferred from CDP-Cho to the GalNac residues (green) of glycan precursors
(RXN 3). The glycan precursors then assemble to form pre-teichoic acids (RXN 4), which become
either LTA or CTA molecules depending on their final destination. LTA and CTA are embedded in
the membrane or cell wall, respectively.
These are lipoteichoic acid (LTA) and cell wall teichoic acid (CTA) [150,151]. The LicC
cytidylyl transferase catalyzes the production of CDP-choline from PCho (Figure 6, RXN 2).
The LicD1 and LicD2 PCho transferases transfer the PCho to the N-acetylgalactosamine
(G lNac) residues found on pre-teichoic acid glycan precursors (Figure 6, RXN 3) [152].
The precursers are then assembled by an uncharacterized enzyme into variably sized
pre-teichoic a id molecules, (Figur 6, RXN 4) [152]. Pre-teichoic acid transpor across the
cell membrane then mediated by the teichoic acid flippase TacF to become eithe LTA r
CTA. LTA and CTA are chemically similar, wi th difference that LTA is embedded in the
cell membrane via a glycolipid lipid an or through the action of the TacL ligase [153], and
CTA is covalently attached to the cell wall via peptidoglycan molecules through the action
of LCP phosphotransferases [145]. M anwhile LTA is a known viru ence factor and the
LTA synthesis pat way has demonstrated to be a source of drug targets [154].
Sign ficantly, LidD2 knockouts of S. pn umoniae diminish virulence due t limitations
in the number of PCho containing teichoic acids found on the cell surface [155]. PCho
decoration of the cell surface is required for or al c ll-functioning because the Cho moiety
a c ors choline binding protei s (CBPs) such as murein ydrolases LytA and LytaAB,
which are critical factors for cell division [156]. In addition, it anchors the choline binding
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protein A (CBPA) which is a determinant of virulence [157]. Many other CBPs are involved
in colonization and even sepsis [158]. Therefore, the choline metabolic pathways, of which
sChoK is an integral part, play an important role in S. pneumoniae growth and invasion.
Disrupting the teichoic acid production pathway can also disrupt S. pneumonaie cell
growth. Therefore, it follows that disruption of any element of this pathway, such as
sChoK, is a promising therapeutic avenue to follow. In addition, the same tools used the
to inhibit eukaryotic ChoKs are likely to be effective against sChoK, particularly those
know to interact with the substrate binding sites. This is because the choline and ATP sites
of sChoks are highly conserved with respect to eukaryotic isoforms (Figure 4) as are the
tertiary structures.
With this rationale in mind, the well-known choline analog and competitive hChoKI
was studied and found to inhibit sChoK and cell growth with a high IC50 (in the mM
range). This was also found to disrupt lipoteichoic acid production, which was consistent
with the cell wall deformations that were observed by scanning electron microscopy.
This established sChoK as a putative drug target [159–161]. Later, the hChoK inhibitors
MN58b and RSM-932A were assayed and found to inhibit both sChoK activity and S.
pneumoniae cell growth at moderate and low µM concentrations, to modulate lipoteichoic
acid production and assembly, and to affect the cell wall. Interestingly, in the case of
in vitro studies with purified sChoK, MN58 functions as a competitive inhibitor against
both choline and ATP, while RSM932A functions as a competitive and non-competitive
inhibitor against choline and ATP, respectively. This result against RSM932A is in sharp
contrast to the observed uncompetitive behavior of this drug in the case of pf-ChoK. This
indicates that there are likely enough differences in the largely conserved active sites of the
different ChoKs to modulate ChoKI behavior. This promising outcome suggests that it will
likely be possible to rationally design ChoKI that are effective but selective between the
different isoforms.
9.2. Haemophilius influenzae ChoK
The choline kinase of Haemophilius influenzae (hiChoK) is another promising target to
explore for the design of inhibitors against this pathogen. Cho is not a nutritional require-
ment in the case of the Gram-negative H. influenzae, as it is in S. pneumoniae. Nevertheless,
this pathogen does uptake this metabolite from its surroundings [162], including from
host cells [163] H. influenzae produces PCho and uses it to decorate its lipopolysaccharides
(LPS). PCho containing LPS molecules mediate the interactions between the pathogen
and host and help the pathogen avoid host immune responses [149]. By mimicking the
phosphatidylcholine of eukaryotic host cells, these LPS molecules shield the pathogen
from attack from host cell produced anti-microbial peptides [164] and antibodies [165]. It
is important to note that the LicA gene that codes for hiChoK is upregulated during the
colonization steps of H. influenzae [166]. PCho is also important for pathogenesis of H.
influenzae, because this molecule mediates cell adhesion to the host PAF receptor [162] in a
step which leads to invasion the respiratory tract [149]. In addition, PCho decoration of
lipoteichoic acid has been shown to reduce the binding of a bacteriocidal antibodies [164].
10. Rheumatoid Arthritis and Inflammation
In animal models of rheumatoid arthritis (RA), ChoKIαs are also very successful,
suggesting that these drugs have the potential to be used as potent therapeutics in inflam-
matory diseases [167]. Cell migration and resistance to apoptosis of cultured fibroblast-like
synoviocytes (FLS), which are involved in cartilage destruction in RA, were suppressed
by MN58b, a powerful specific ChoKαI. ChoKα inhibition with MN58b significantly de-
creased FLS migration and proliferation, and abrogated joint inflammation and damage in
either pretreatment or proven disease protocols in the K/BxN arthritis mouse model [167].
These findings are in keeping with studies that postulate that synovial inflammation,
hyperplasia, and joint destruction are all hallmarks of RA [168]. Phosphoinositide 3-kinase
(PI3K)/Akt and Mitogen-activated protein kinase (MAPK) are involved in the control of
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FLS activity in RA, including matrix metalloproteinases (MMP) expression, synoviocyte
growth and survival, and are the subject of therapeutic intervention in RA [169]. As
previously mentioned, MN58b selectively inhibits ChoKα, which inhibits MAPK and
PI3K/Akt signalling [103–105], while PI3K inhibition affects ChoK function [170]. Finally,
disruption of ChoKα activity affects phosphorylation of Rb, downmodulates cyclin D1,
and interferes with PDGF signaling in FLS, as previously demonstrated in other cell
systems [62].
Using the C. Elegans as a model for Parkinson’s disease (PD), it has been suggested that
ChoK may be an important player in PD since inhibition of its expression by siRNA signifi-
cantly reduces the nuclear localization of Daf-16. ChoK silenced worms showed decreased
lipid content, a parameter of immense importance in PD-associated endpoints [113].
Furthermore, ChoKα inhibitors have been shown to be very active in the treatment
of several animal models for human diseases related to dysregulation of the inflamma-
some [171]. Thus, in the LPS-induced septic shock model, ChoKα inhibition dramatically
reduced LPS-induced death, an effect associated with reduced levels of circulating IL-
1β. Additionally, ChoKα inhibition has therapeutic effects in three models of chronic
syndromes associated with cryopyrin (CAPS): Muckle–Wells syndrome (MWS), familial
cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory
disease (NOMID). These three syndromes are a consequence of mutations in the NLRP3
gene that cause chronic activation of the inflammasome [171]. Therefore, ChoKα inhibition
may play an important role in the treatment of a diversity of human diseases related to an
altered inflammatory response.
11. Future Perspectives: ChoKIs Development for the Treatment of Cancer, Arthritis,
Inflammation, Infections and Beyond
ChoKα is overexpressed in a large number of human tumors, and blocking its function
causes cancer cells to die while non-tumorigenic cells undergo a reversible cell cycle arrest.
Based on a novel mechanism of action, it makes possible combination of ChoK inhibitors
with many current therapeutic approaches. Thus, specific targeting of this enzyme is a novel
strategy for the treatment of many cancer types. Other diseases for which ChoKα inhibitors
have been shown to be effective include malaria, rheumatoid arthritis, inflammation,
parasites, and pathogenic bacteria.
One of our ChoKα inhibitors, RSM932A/TCD717, has reached the first in human
Phase I clinical trial [79]. This first step towards the use of this novel family of drugs
in the regular clinical practice has been a milestone that has paved the way for future
development of successful drugs. Although further work is needed to finally reach the
clinic as a standard of care in any of the several pathological conditions where ChoKIs have
been proposed as a therapeutic strategy, the most important issues as the preclinical and
the toxicology studies have been already addressed.
There is limited research into ChoKIs of parasites and therefore a limited number
of promising ChoK drug leads. Likewise, much of this research has not yet reached the
pre-clinical stage, nor therefore Phase I trials. Given this dearth in research, repurposing
hChoK inhibitors may be good strategy for discovering novel treatments for parasites. As
hChoKIs become cleared for use in humans to treat pathologies such as cancer, rheumatoid
arthritis and inflammation, the immense amount of research required to reach that point
can be exploited to find new treatments for illnesses such as malaria.
Despite the importance of hiChoK in pathogenesis of H. influenzae, the idea that
hiChoK could function as a therapeutic target, remains untested. While, hiChoK has not
yet been identified as an enzyme critical for cell growth, it is likely that inhibitors for this
enzyme could be developed and employed as therapeutic adjuncts designed to assist the
immune system in defending against infection.
Meanwhile, the improvements in sChoK inhibition observed with MN58b and RSM932A
fully validated the idea that inhibitors of eukaryotic ChoKs could be repurposed for use
against prokaryotes [172,173]. However, sChoK still needs to be fully validated as the
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drug target responsible for these physiological effects and further metabalonomic and/or
mutational studies need to be carried to fully establish this system.
In addition, more refined research needs to be carried out to fully distinguish the
effects that these drugs might have on other choline binding proteins such as the autolysin
LytA and many others [156]. The autolysin LytA mediates cell autolysis in S. pneumoniae,
therefore, as an initial step, any putative sChoK inhibitor should also be assayed for
its ability to modulate the autolytic process [171,172]. For example, HC-3 is known to
modulate autolysis [174], but MN58b and RSM932A do not. Precision about the actual
drug targets is necessary. However, more than one target for putative sChoK inhibitor
would actually be highly beneficial. Multiple disruptions in more than one part of the
choline metabolism or choline binding pathway may help prevent the development of new
resistance to this novel family of inhibitors.
ChoK and other CBPs may be produced by other many bacterial species. Therefore,
ChoKIs, like many other drugs [175] may affect species found in the human microbiome.
Future studies will need to take these possible effects into account in determine the effects
of ChoKIs on human health. The final goal should be to develop a ChoKI therapeutic that
is specific to microbial choline kinases, and preferably targeted against specific pathogenic
species. Preventing unintended consequences will require a more complete and rational-
ized understanding of the structural differences between the different ChoKs and CPBs of
the various species.
Recently, a functional relationship between the immune checkpoint programmed cell
death protein-1 (PD-1) and ChoKα has been established [176]. PD-L1 regulates metabolism
through ChoKα, COX-2, and TGF-β, a new twist in the application of combinatorial
therapies targeting both the immune checkpoints and modulation of critical enzymes
involved in cancer metabolism. Thus, a new door has been opened to further investigate a
potential relationship of ChoKα and the immune response.
Finally, since the mechanism of action of ChoKα inhibitors is based on the inhibition
of the production of the ILs responsible for these inflammatory processes [166,170] there
is another potential application. ChoKαIs reduce macrophage activation and NLRP3
inflammasome attenuating the inflammatory response by modulating the production
of IL-6, IL-1β and IL-18. All these processes are carried out by inhibiting ChoKα, the
therapeutic target of our inhibitors. COVID-19 patients present in its most acute phases the
Severe Acute Respiratory Syndrome (SARS), caused by strong bilateral lung inflammation,
responsible for their death. This inflammatory process is associated with a strong increase
in cytokine levels mediated by the inflammasome [177] process that coincides with studies
carried out with SARS-Cov in which a relationship with the activation of the NLRP3
inflammasome was observed [178]. Based on these observations, it is reasonable to assume
that inhibition of the phosphatidylcholine synthesis pathway through inhibition of the
ChoKα enzyme could be an effective treatment in COVID-19 patients in the most advanced
stages of the disease. This also deserves further investigation.
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